Report cover image

Patient Derived Xenograft/PDX Models

Publisher Global Industry Analysts
Published Oct 01, 2022
Length 192 Pages
SKU # GJOB17451819

Description

Patient Derived Xenograft/PDX Models

Global Patient Derived Xenograft / PDX Models Market to Reach $333.2 Million by 2027

In the changed post COVID-19 business landscape, the global market for Patient Derived Xenograft / PDX Models estimated at US$115.7 Million in the year 2020, is projected to reach a revised size of US$333.2 Million by 2027, growing at aCAGR of 16.3% over the period 2020-2027. Mice Model, one of the segments analyzed in the report, is projected to record 17.7% CAGR and reach US$255 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Rat Model segment is readjusted to a revised 12.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $33.4 Million, While China is Forecast to Grow at 15.3% CAGR

The Patient Derived Xenograft / PDX Models market in the U.S. is estimated at US$33.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$56.9 Million by the year 2027 trailing a CAGR of 15.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.9% and 13.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR.

Select Competitors (Total 38 Featured) -

  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Epo Berlin-Buch GmbH
  • Hera BioLabs
  • Oncodesign
  • Pharmatest Services Ltd.
  • The Jackson Laboratory
  • Urolead SAS
  • WuXi AppTec
  • Xentech
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

192 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Patient Derived Xenograft/PDX Models – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 2: World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
TABLE 3: World Recent Past, Current & Future Analysis for Mouse by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 4: World 7-Year Perspective for Mouse by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
TABLE 5: World Recent Past, Current & Future Analysis for Rat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 6: World 7-Year Perspective for Rat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 8: World 7-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
TABLE 9: World Recent Past, Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 10: World 7-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
TABLE 11: World Recent Past, Current & Future Analysis for Pharma & Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 12: World 7-Year Perspective for Pharma & Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 14: World 7-Year Perspective for CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
TABLE 15: World Patient Derived Xenograft/PDX Models Market Analysis of Annual Sales in US$ for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 16: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 17: USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 18: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 19: USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 20: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 21: USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
CANADA
TABLE 22: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 23: Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 24: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 25: Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 26: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 27: Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
JAPAN
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 28: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 29: Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 30: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 31: Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 32: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 33: Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
CHINA
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 34: China Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 35: China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 36: China Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 37: China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 38: China Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 39: China 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
EUROPE
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 40: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
TABLE 41: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
TABLE 42: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 43: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 44: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 45: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 46: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 47: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
FRANCE
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 48: France Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 49: France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 50: France Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 51: France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 52: France Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 53: France 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
GERMANY
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 54: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 55: Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 56: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 57: Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 58: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 59: Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
ITALY
TABLE 60: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 61: Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 62: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 63: Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 64: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 65: Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
UNITED KINGDOM
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 66: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 67: UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 68: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 69: UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 70: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 71: UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
REST OF EUROPE
TABLE 72: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 73: Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 75: Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 77: Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
ASIA-PACIFIC
Patient Derived Xenograft/PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 78: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 79: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 81: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 83: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
REST OF WORLD
TABLE 84: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 85: Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2021 & 2027
TABLE 86: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 87: Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2021 & 2027
TABLE 88: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
TABLE 89: Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2021 & 2027
IV. COMPETITION

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us